United Therapeutics (UTHR)
(Real Time Quote from BATS)
$301.44 USD
-3.37 (-1.11%)
Updated Aug 6, 2025 03:20 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UTHR 301.44 -3.37(-1.11%)
Will UTHR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline
Other News for UTHR
United Therapeutics (UTHR) Launches $1 Billion Share Buyback
United Therapeutics (UTHR) Launches $1B Stock Buyback Program
United Therapeutics enters $1B accelerated share repurchase program
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program | ...
United Therapeutics announces $1B accelerated share repurchase program